Loading
A phase 3 trial of AB-205 run by Angiocrine Bioscience, terminated.
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation is a phase 3 interventional study registered as NCT05181540 by Angiocrine Bioscience, with 130 participants enrolled, started 2022-02-21. Conditions recorded: Hodgkin Lymphoma and Non Hodgkin Lymphoma. Interventions recorded: AB-205 and Placebo.
Shares AB-205, Angiocrine Bioscience, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/